Moleculin Biotech, Inc. (MBRX) compared with its closest peers (ADIL, HIND, BIVI, PHIO, KPRX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $16.33M | -0.0 |
| Vyome Holdings, Inc. (HIND) | $16.14M | -0.7 |
| BioVie Inc. (BIVI) | $14.71M | -0.6 |
| Phio Pharmaceuticals Corp. (PHIO) | $13.71M | -0.7 |
| Kiora Pharmaceuticals, Inc. (KPRX) | $11.44M | -0.7 |
| Aspire Biopharma Holdings, Inc. (ASBP) | $11.21M | -0.0 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $10.81M | — |
| Theriva Biologics, Inc. (TOVX) | $10.67M | -0.1 |
| MetaVia Inc. (MTVA) | $9.65M | -1.1 |
| Imunon, Inc. (IMNN) | $9.20M | -0.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
MBRX overview · MBRX earnings · MBRX financials · MBRX KPIs · MBRX investor relations · MBRX ownership · MBRX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.